Pipeline

SPECIALPROJECTS

Science Biotech connects clinical research, regulatory expertise, academia and the pharmaceutical industry to accelerate healthcare innovation.

Clinical research and regulatory affairs expertise, with global trial recruitment, successful ANVISA registrations, and partnerships with international universities, including the University of Michigan, University of Chicago, Loyola University Chicago, University of Aveiro, and UNESP.
Clinical research and regulatory affairs expertise, with global trial recruitment, successful ANVISA registrations, and partnerships with international universities, including the University of Michigan, University of Chicago, Loyola University Chicago, University of Aveiro, and UNESP.
Pipeline de pesquisa clínica
Pipeline de pesquisa clínica

EXPLORE OUR PROGRAMS – CLICK ON ANY ONE TO LEARN MORE

2024CRSD COVID intranasal vaccine development pipeline by FioCruz, showing preclinical validation and progression toward Phase 1, with a US$5 million funding target for Phase 1 execution. The patented vaccine candidate has no commercial partner yet and focuses on COVID-19, intranasal vaccination, and infectious diseases.
2024CRSD COVID intranasal vaccine development pipeline by FioCruz, showing preclinical validation and progression toward Phase 1, with a US$5 million funding target for Phase 1 execution. The patented vaccine candidate has no commercial partner yet and focuses on COVID-19, intranasal vaccination, and infectious diseases.
Ovinox thromboprophylaxis and treatment pipeline for venous thromboembolism and pulmonary embolism (VTE/PE), showing development stages from Discovery to Phase 3, subcutaneous administration, funding information, and cardiovascular disease applications.
Ovinox thromboprophylaxis and treatment pipeline for venous thromboembolism and pulmonary embolism (VTE/PE), showing development stages from Discovery to Phase 3, subcutaneous administration, funding information, and cardiovascular disease applications.
Femmenox development pipeline for thromboprophylaxis and treatment of venous thromboembolism (VTE) during pregnancy and the puerperium. Repurposing of enoxaparin with a patented delivery device, currently in final development, with a US$9.6 million funding target for approval. Subcutaneous administration and gynecology applications.
Femmenox development pipeline for thromboprophylaxis and treatment of venous thromboembolism (VTE) during pregnancy and the puerperium. Repurposing of enoxaparin with a patented delivery device, currently in final development, with a US$9.6 million funding target for approval. Subcutaneous administration and gynecology applications.
ClaudiBOLT clinical development pipeline for intermittent claudication, a cardiovascular condition. The infographic presents development stages from Discovery to Phase 3, oral administration, and funding information for the drug development program.
ClaudiBOLT clinical development pipeline for intermittent claudication, a cardiovascular condition. The infographic presents development stages from Discovery to Phase 3, oral administration, and funding information for the drug development program.
Atherovax clinical development pipeline for atherosclerosis and inflammatory cardiovascular diseases. The infographic highlights a patented vaccine candidate, preclinical development stages through Phase 3, subcutaneous administration, and a US$500,000 funding target to reach Phase 1.
Atherovax clinical development pipeline for atherosclerosis and inflammatory cardiovascular diseases. The infographic highlights a patented vaccine candidate, preclinical development stages through Phase 3, subcutaneous administration, and a US$500,000 funding target to reach Phase 1.
Colitivax clinical development pipeline for Crohn's disease and ulcerative colitis, featuring a patented investigational vaccine for inflammatory bowel disease (IBD). The infographic shows development stages from Discovery to Phase 3, subcutaneous administration, and a US$500,000 funding target to reach Phase 1.
Colitivax clinical development pipeline for Crohn's disease and ulcerative colitis, featuring a patented investigational vaccine for inflammatory bowel disease (IBD). The infographic shows development stages from Discovery to Phase 3, subcutaneous administration, and a US$500,000 funding target to reach Phase 1.
PX2024 antidepressant supplement development pipeline, featuring an incremental antidepressant candidate with a patent pending and partner negotiations underway. The infographic shows development stages from Discovery to Phase 3, oral administration, and a US$500,000 funding target for launch, with applications in supplements and psychiatry.
PX2024 antidepressant supplement development pipeline, featuring an incremental antidepressant candidate with a patent pending and partner negotiations underway. The infographic shows development stages from Discovery to Phase 3, oral administration, and a US$500,000 funding target for launch, with applications in supplements and psychiatry.
PS2025 clinical development pipeline for varicose veins and lipedema, featuring SB002, a radical active pharmaceutical ingredient in production, with a patent in preparation. The infographic shows development stages from Discovery to Phase 3, oral administration, a US$2 million funding target to reach Phase 1, and a licensing opportunity for a global pharmaceutical partner.
PS2025 clinical development pipeline for varicose veins and lipedema, featuring SB002, a radical active pharmaceutical ingredient in production, with a patent in preparation. The infographic shows development stages from Discovery to Phase 3, oral administration, a US$2 million funding target to reach Phase 1, and a licensing opportunity for a global pharmaceutical partner.
2025MC male contraceptive development pipeline, featuring an experimental oral contraceptive candidate in the proof-of-concept stage, with development not yet started. The project is funded by CNPq and conducted through international collaboration, with a US$1 million funding target to reach Phase 1 and applications in andrology and urology.
2025MC male contraceptive development pipeline, featuring an experimental oral contraceptive candidate in the proof-of-concept stage, with development not yet started. The project is funded by CNPq and conducted through international collaboration, with a US$1 million funding target to reach Phase 1 and applications in andrology and urology.